PASTEUR Act of 2026

PASTEUR Act of 2026 – Plain English Summary

Please note: No official bill text or description was provided for this legislation, so this summary is based on the bill's title and the limited information available. The PASTEUR Act (which likely stands for Pioneering Antimicrobial Subscriptions to End Upsurging Resistance) appears to be a reintroduction or continuation of legislation that has been considered in previous congressional sessions related to combating antibiotic resistance — one of the most serious public health threats facing the country.

Based on prior versions of this bill, the legislation would generally create a new way for the federal government to pay pharmaceutical companies to develop new antibiotics and antimicrobial drugs. Instead of paying based on how many doses are sold (which gives drug companies little financial incentive to develop antibiotics that are used sparingly), the government would pay a set subscription-like fee in exchange for guaranteed access to new, effective antibiotics. This approach is meant to encourage drug companies to invest in developing treatments for dangerous, drug-resistant infections.

The bill would affect patients, hospitals, and the broader public health system by working to ensure that effective antibiotics are available when needed — particularly for life-threatening infections that no longer respond to existing drugs. It would also affect pharmaceutical companies, potentially providing a more stable financial reward for developing these critical medicines.

The bill has been referred to the House Committees on Energy and Commerce and the Budget, meaning it is still in early stages. *Because no official bill text was provided, readers are encouraged to consult Congress.gov for the full and accurate details of this specific version.*